外用溴芬酸联合玻璃体内注射阿弗利百普治疗渗出性年龄相关性黄斑变性的临床疗效

Pub Date : 2024-01-15 DOI:10.3341/jkos.2024.65.1.27

Mi Sun Kwon, Jin Young Kim, Yu Min Kim, J. R. Do, Yong Koo Kang, J. Shin, D. Park

{"title":"外用溴芬酸联合玻璃体内注射阿弗利百普治疗渗出性年龄相关性黄斑变性的临床疗效","authors":"Mi Sun Kwon, Jin Young Kim, Yu Min Kim, J. R. Do, Yong Koo Kang, J. Shin, D. Park","doi":"10.3341/jkos.2024.65.1.27","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the efficacy of topical bromfenac combined with intravitreal aflibercept (IVA) injection in the treatment of exudative age-related macular degeneration over a 2-year period.Methods: We retrospectively studied 43 patients (43 eyes) with exudative age-related macular degeneration. Patients were included if they received IVA injections under an as-needed protocol and had > 2 years of follow-up. Among the 43 eyes, 25 received only IVA (IVA group), whereas 18 received a combination of IVA and topical bromfenac (bromfenac group). The primary outcome measure was the total number of IVA injections administered over 2 years from the initial injection compared between groups. We also compared changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) between groups.Results: The bromfenac group received a significantly lower number of IVA injections over 2 years (7.4 ± 1.0), compared with the IVA group (9.0 ± 1.9) (p < 0.01). Both groups showed improvements in BCVA and CRT after 2 years compared with their baseline values. However, changes in BCVA and CRT at 2 years did not significantly differ between groups (p = 0.786 and p = 0.905, respectively).Conclusions: Among patients with exudative age-related macular degeneration, the total number of IVA injections over 2 years was lower in the bromfenac group than in the IVA group. More studies are needed to confirm the efficacy of topical bromfenac in a combined treatment regimen.","PeriodicalId":0,"journal":{"name":"","volume":" 48","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Outcomes of Topical Bromfenac Combined with Intravitreal Aflibercept Injection for Exudative Age-related Macular Degeneration\",\"authors\":\"Mi Sun Kwon, Jin Young Kim, Yu Min Kim, J. R. Do, Yong Koo Kang, J. Shin, D. Park\",\"doi\":\"10.3341/jkos.2024.65.1.27\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To evaluate the efficacy of topical bromfenac combined with intravitreal aflibercept (IVA) injection in the treatment of exudative age-related macular degeneration over a 2-year period.Methods: We retrospectively studied 43 patients (43 eyes) with exudative age-related macular degeneration. Patients were included if they received IVA injections under an as-needed protocol and had > 2 years of follow-up. Among the 43 eyes, 25 received only IVA (IVA group), whereas 18 received a combination of IVA and topical bromfenac (bromfenac group). The primary outcome measure was the total number of IVA injections administered over 2 years from the initial injection compared between groups. We also compared changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) between groups.Results: The bromfenac group received a significantly lower number of IVA injections over 2 years (7.4 ± 1.0), compared with the IVA group (9.0 ± 1.9) (p < 0.01). Both groups showed improvements in BCVA and CRT after 2 years compared with their baseline values. However, changes in BCVA and CRT at 2 years did not significantly differ between groups (p = 0.786 and p = 0.905, respectively).Conclusions: Among patients with exudative age-related macular degeneration, the total number of IVA injections over 2 years was lower in the bromfenac group than in the IVA group. More studies are needed to confirm the efficacy of topical bromfenac in a combined treatment regimen.\",\"PeriodicalId\":0,\"journal\":{\"name\":\"\",\"volume\":\" 48\",\"pages\":\"\"},\"PeriodicalIF\":0.0,\"publicationDate\":\"2024-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3341/jkos.2024.65.1.27\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3341/jkos.2024.65.1.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的：评估局部溴芬酸与玻璃体内注射阿弗利百普（IVA）治疗渗出性年龄相关性黄斑变性的疗效：我们对43例（43眼）渗出性年龄相关性黄斑变性患者进行了回顾性研究。根据需要接受 IVA 注射且随访时间超过 2 年的患者均被纳入研究范围。在这43只眼睛中，25只只接受了IVA注射（IVA组），而18只接受了IVA和局部溴芬酸的联合治疗（溴芬酸组）。主要结果指标是比较两组患者在首次注射后两年内注射 IVA 的总次数。我们还比较了组间最佳矫正视力（BCVA）和视网膜中央厚度（CRT）的变化：结果：与 IVA 组（9.0 ± 1.9）相比，溴芬酸组在 2 年内接受 IVA 注射的次数（7.4 ± 1.0）明显较少（p < 0.01）。与基线值相比，两组患者 2 年后的 BCVA 和 CRT 均有所改善。然而，2 年后 BCVA 和 CRT 的变化在组间并无显著差异（分别为 p = 0.786 和 p = 0.905）：结论：在渗出性年龄相关性黄斑变性患者中，溴芬酸组在2年内注射IVA的总次数低于IVA组。还需要更多的研究来证实溴芬酸外用药在联合治疗方案中的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

Clinical Outcomes of Topical Bromfenac Combined with Intravitreal Aflibercept Injection for Exudative Age-related Macular Degeneration

Purpose: To evaluate the efficacy of topical bromfenac combined with intravitreal aflibercept (IVA) injection in the treatment of exudative age-related macular degeneration over a 2-year period.Methods: We retrospectively studied 43 patients (43 eyes) with exudative age-related macular degeneration. Patients were included if they received IVA injections under an as-needed protocol and had > 2 years of follow-up. Among the 43 eyes, 25 received only IVA (IVA group), whereas 18 received a combination of IVA and topical bromfenac (bromfenac group). The primary outcome measure was the total number of IVA injections administered over 2 years from the initial injection compared between groups. We also compared changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) between groups.Results: The bromfenac group received a significantly lower number of IVA injections over 2 years (7.4 ± 1.0), compared with the IVA group (9.0 ± 1.9) (p < 0.01). Both groups showed improvements in BCVA and CRT after 2 years compared with their baseline values. However, changes in BCVA and CRT at 2 years did not significantly differ between groups (p = 0.786 and p = 0.905, respectively).Conclusions: Among patients with exudative age-related macular degeneration, the total number of IVA injections over 2 years was lower in the bromfenac group than in the IVA group. More studies are needed to confirm the efficacy of topical bromfenac in a combined treatment regimen.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助